Ulcerative Colitis after Administration of Dupilumab, an Anti-interleukin-4 Receptor Subunit α Monoclonal Antibody

Le résumé fourni par la source

We report the case of a 38-year-old woman who visited our hospital because of persistent bloody stool one month after starting treatment with dupilumab, an anti-interleukin-4 receptor subunit α monoclonal antibody, for bronchial asthma. Based on the lower gastrointestinal endoscopy findings, the patient was diagnosed with ulcerative colitis. Despite medication, the patient's bloody stool was not well controlled; however, the situation improved after discontinuation of dupilumab. Based on the patient's clinical course, drug-induced ulcerative colitis due to dupilumab was diagnosed. Careful monitoring of the symptoms associated with the development of enteritis is necessary after dupilumab administration.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.